| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Anika Therapeutics Inc.$15.6
-0.49 (-3.05%)
D 37Pipeline Score MedTech · Commercial
Market Cap
191.33 M
EPS
-0.79
P/E Ratio
-18.18 $
Value Trade
708.69 K
SEC Financials
Q1 2026Dilution Risk
Revenue
29.61 M
R&D Expenses
6.71 M
Operating CF
-4.85 M
Total Assets
179.39 M
Total Liabilities
179.39 M
Equity
133.90 M
D/E Ratio
12,345
-1.85 %
Week
-1.78 %
1 Month
39.46 %
3 Month
59.83 %
6 Month
-65.71 %
5 Year
325.14 %
All Time
Cash Data
Cash Position
66.79 M
Monthly Burn
1.61 M
Runway
39.3 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
46.92 K
52 Week Range
7.87 - 16.24
% held by Insiders
6.31 %
% held by Institutions
93.25 %
Enterprise Value
176.05 M
Total Shares
14.42 M
Short %
3.29 %
Float Shares
12.68 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D37
Pipeline Score $269M
Pipeline ValueValuation Signal
1
Drugs Scored1.4x
rNPV / MCap Top 53%
Micro Cap (rank 429 of 911)
Percentile RankAnika Therapeutics Inc. faces pipeline headwinds (37/100), with $1.1B risk-adjusted pipeline value, led by Cingal in Osteoarthritis of the Knee (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cingal Small molecule | Knee Osteoarthritis | Phase 3 | NCT03390036 | 58% | $1.1B | COMPLETED | 1,102 | - | - | Jul 30, 2018 | - | May 31, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Hyalofast | articular cartilage defects in the knee | Phase 3 | 2025-11-05 | KOOS Pain difference: 8.11%; IKDC Function difference: 4.84%; Hyalofast KOOS Pain improvement: 4.54 points; Hyalofast IKDC improvement: 2.19 points; Hyalofast observed data improvement: 23.37% Read More | Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study Read More | |
Hyalofast | articular cartilage defects in the knee | Phase 3 | 2025-11-05 | KOOS Pain difference: 8.11%; IKDC Function difference: 4.84%; Hyalofast KOOS Pain improvement: 4.54 points; Hyalofast IKDC improvement: 2.19 points; Hyalofast observed data improvement: 23.37% Read More | Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study Read More | |
Hyalofast | articular cartilage defects in the knee | Phase 3 | 2025-11-05 | KOOS Pain difference: 8.11%; IKDC Function difference: 4.84%; Hyalofast KOOS Pain improvement: 4.54 points; Hyalofast IKDC improvement: 2.19 points; Hyalofast observed data improvement: 23.37% Read More | Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANIK
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANIK Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANIKSummer Activities and Foods That Support Joint Health
The article discusses how summer activities and foods can support joint health. It highlights low-impact exercises such as swimming, cycling, and gentle yoga that are beneficial for joint mobility. Additionally, it emphasizes the importance of incorporating anti-inflammatory foods like omega-3 fatty acids and berries into the diet. Small, consistent changes can lead to significant improvements in joint health.
Read more →ANIKUnexplained Bone Pain? Understanding Insufficiency Fractures and Tactoset
The article discusses insufficiency fractures, which are small cracks in the bone caused by gradual stress rather than a single incident. It highlights the challenges in diagnosing these fractures, as they often do not appear on standard X-rays. Tactoset, a treatment made from calcium phosphate and hyaluronic acid, is introduced as a minimally invasive option to support healing in chronic cases. The article emphasizes the importance of consulting with a doctor for persistent bone pain.
Read more →ANIKOsteoarthritis and Inflammation: Understanding What’s Happening Inside the Joint
The article discusses the role of joint inflammation in osteoarthritis, emphasizing its impact on joint health and movement. It explains how chronic inflammation can lead to pain and reduced mobility, while also highlighting lifestyle changes that can help manage inflammation. Treatments based on hyaluronic acid are presented as a potential solution for improving joint function.
Read more →ANIKAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. has announced the granting of restricted stock units (RSUs) to a newly hired non-executive employee as part of its 2021 Inducement Plan. This grant includes a total of 3,360 shares, which will vest in three equal installments over the next three years, contingent on the employee's continuous service. This action was taken to incentivize the new hire and is compliant with Nasdaq Listing Rule 5635(c)(4). Anika's focus remains on osteoarthritis pain management and regenerative solutions.
Read more →ANIKWhat Is <span class="notranslate" translate="no">Cingal</span>? A Proven Joint Injection for Osteoarthritis Pain
Cingal is a single-injection treatment for knee osteoarthritis pain, combining hyaluronic acid and a corticosteroid for effective relief. With over a million injections performed globally, it provides rapid and sustained pain relief. However, it is not currently approved in the U.S., and patients should consult their doctors regarding its availability.
Read more →ANIKCan the Body Heal Joint Tissue on its Own?
The article discusses the challenges of healing joint tissues, particularly tendons and cartilage, due to their limited blood supply. It highlights the role of regenerative medicine and treatments like hyaluronic acid and scaffolds in supporting the healing process. The Integrity implant and Hyalofast scaffold are mentioned as potential options for tendon and cartilage injuries, respectively.
Read more →ANIKThe Science of Healing: How Biologic Scaffolds Support Your Body’s Recovery
The article discusses the advancements in orthopedic care through biologic scaffolds, which support the body’s healing process by providing a structure for tissue regeneration. These scaffolds can be made from natural or synthetic materials and are used in various orthopedic surgeries. Notable products like Hyaff and Integrity are highlighted for their effectiveness in cartilage and tendon repair, respectively.
Read more →ANIK▼ -18.8%on this newsshared move
Anika Reports First Quarter 2026 Financial Results
Anika Therapeutics reported a 13% increase in total revenue for Q1 2026, reaching $29.6 million, driven by strong performance in both Commercial and OEM Channels. The company achieved a gross margin of 64.2%, up from 56.1% the previous year, and reported an adjusted EBITDA of $4.3 million. However, operating expenses rose significantly due to severance costs, and the company faces ongoing challenges with FDA approvals.
Read more →ANIKAnika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Anika Therapeutics, Inc. will announce its first quarter 2026 financial results on April 29, 2026. The announcement will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Read more →ANIKTendon Repair: How The <span class="notranslate" translate="no">Integrity</span> Implant Supports Your Return to Active Living
The article discusses the challenges of tendon injuries and introduces Anika's Integrity Implant as a solution for enhancing healing. This biologic scaffold supports tendon repair by creating an optimal healing environment, utilizing hyaluronic acid without animal-derived materials. The Integrity Implant aims to improve recovery times and outcomes for patients with tendon injuries, allowing them to return to active lifestyles more effectively.
Read more →ANIKSpring Into Motion: The Best Season to Get Your Joints Moving
The article emphasizes the importance of keeping joints active, especially during spring when outdoor conditions are favorable. It suggests various low-impact activities such as walking, cycling, swimming, and yoga that can help maintain joint health. The piece encourages readers to consult healthcare professionals before starting new activities and to listen to their bodies while exercising. Overall, it promotes a proactive approach to joint care during the spring season.
Read more →ANIKRepairing Cartilage Injuries: How <span class="notranslate" translate="no">Hyalofast</span> Works in the Knee
Hyalofast is a regenerative medicine solution designed to repair cartilage injuries in the knee. Made from hyaluronic acid, it acts as a scaffold to support the body's natural healing processes. Clinical studies indicate that it leads to durable cartilage regeneration and improved knee function over time. The procedure is minimally invasive and can be performed in a single stage.
Read more →ANIK▲ +16.9%on this news· ran to +32% by day 3
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Anika Therapeutics reported its financial results for Q4 and the full year 2025, showing a 22% increase in Commercial Channel revenue. Despite a 6% decrease in total revenue year-over-year, the company achieved positive operating cash flow and expanded gross margins. Anika is focused on advancing its product portfolio and has reaffirmed its guidance for 2026.
Read more →ANIKAnika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika Therapeutics, Inc. has announced that its President and CEO, Steve Griffin, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on March 2, 2026. The company will also hold one-on-one meetings with investors during the event. The presentation will be accessible via live webcast and archived on Anika’s website for 30 days. Anika focuses on advancements in orthopedic care, particularly in the fields of osteoarthritis pain management and regenerative solutions.
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. will announce its fourth quarter and year-end 2025 financial results on February 26, 2026. Before the market opens, stakeholders can access a conference call at 8:30 a.m. ET to discuss these results and business highlights. Anika, a global joint preservation company headquartered outside Boston, emphasizes advancements in minimally invasive orthopedic care, particularly in pain management and regenerative solutions.
Read more →ANIKLumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors
Lumicell, Inc. has appointed Cheryl R. Blanchard, Ph.D., to its Board of Directors. Dr. Blanchard, a seasoned leader with over 30 years of experience in biotech and medtech, previously served as President and CEO of Anika Therapeutics. Her expertise is anticipated to drive Lumicell's growth and enhance its innovative cancer detection technologies.
Read more →ANIKANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
Bragar Eagel & Squire, P.C. is advising Anika Therapeutics investors about an ongoing investigation into potential violations of federal securities laws by the company. The investigation follows Anika's July 2025 announcement regarding its clinical trial of Hyalofast, which reportedly did not meet its primary endpoints. This news led to a significant drop in Anika's stock price by over 27%, raising concerns among investors about their legal rights and potential losses.
Read more →ANIKAnika Therapeutics Announces Leadership Transition Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive Officer Cheryl Blanchard to Become Executiv
Anika Therapeutics has announced a leadership change as Stephen Griffin will take over as President and CEO on February 1, 2026, succeeding Cheryl Blanchard, who transitions to Executive Chair. Griffin, currently the CFO and COO, holds a strong track record in strategic transformation and operational excellence. Blanchard emphasizes the company's readiness for this change as it shifts focus towards future growth opportunities, reinforcing Anika's role in osteoarthritis pain management. The leadership transition is expected to maintain momentum in the company's strategic initiatives and profitability.
Read more →ANIKAnika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
Kirby McInerney LLP is conducting an investigation into Anika Therapeutics, Inc. for potential securities fraud regarding the company's senior management. This follows Anika's July 30, 2025 announcement that its clinical trial for Hyalofast did not meet its pre-specified endpoints, leading to a substantial drop in its share price. The trial was allegedly affected by a higher dropout rate and missed patient visits, resulting in incomplete data. Interested investors are encouraged to contact the law firm for further information on their rights in this matter.
Read more →ANIKEnd-of-Year Health Check: Planning for a Strong Start to 2026
The article emphasizes the importance of proactive health management as the year ends. It encourages individuals to utilize their health insurance benefits before they reset and to reflect on their health goals. The piece also highlights the advantages of scheduling procedures during quieter winter months and discusses advancements in orthopedic treatments that support recovery. Taking these steps can lead to improved health as one enters 2026.
Read more →ANIKAnika Reports Third Quarter 2025 Financial Results
Anika Therapeutics reported its third-quarter 2025 financial results, highlighting a 22% increase in Commercial Channel revenue despite a 6% decline in overall revenue. The company reaffirmed its fiscal guidance and announced a $15 million share repurchase program. Significant milestones included Cingal surpassing one million injections and the filing of the final module for Hyalofast's PMA application.
Read more →ANIKAnika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Anika Therapeutics has filed the final module of its PMA for Hyalofast, a cartilage repair scaffold. The submission includes 24-month data from the FastTRACK Phase III trial, which showed Hyalofast's potential despite not meeting all primary endpoints. The study indicated significant improvements in secondary endpoints, reinforcing the product's clinical value. Anika aims to work closely with the FDA to bring Hyalofast to market.
Read more →ANIKAnika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
Anika Therapeutics, Inc. announced that it will release its third quarter 2025 financial results on November 5, 2025. Prior to the market opening, a conference call will be held at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via a toll-free number or an international number, and a live webcast will be available on the company's website. Anika Therapeutics focuses on advancements in orthopedic care, particularly in Osteoarthritis Pain Management and Regenerative Solutions.
Read more →ANIKReimagining Achilles Tendon Repair with the <span class="notranslate" translate="no">Integrity</span> Implant
Anika Therapeutics is introducing the Integrity Implant, designed to improve Achilles tendon repair. This implant utilizes Hyaff, a modified hyaluronic acid, to enhance healing by promoting cellular migration and blood vessel formation. A case study demonstrated significant recovery in a patient after surgery with the Integrity Implant, indicating its potential in tendon repair.
Read more →ANIKANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. on behalf of its stockholders. The investigation follows an announcement regarding the disappointing results from a pivotal clinical trial of Anika's Hyalofast product, which did not meet its co-primary endpoints. This led to a significant decline in Anika's stock price. Investors who suffered losses are encouraged to contact the law firm for more information and possible legal options.
Read more →ANIKWhy Choosing a Non-Xenograft Implant Matters
Integrity is a non-xenograft implant designed for tendon repair, utilizing Hyaff and PET materials. This innovative approach addresses patient concerns about animal-derived products, offering a safer and more trusted option. Surgeons are increasingly favoring Integrity due to its biocompatibility and effectiveness in promoting healing. The implant's design supports tissue integration and minimizes immune responses.
Read more →ANIKANIKA ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Anika Therapeutics, Inc. is currently under investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders, focusing on potential violations of federal securities laws. The investigation was prompted by disappointing topline results from a pivotal clinical trial of Hyalofast, which failed to meet its pre-specified co-primary endpoints. Following this announcement, Anika's stock experienced a significant decline of 27.42%. The trial's complications, such as a high dropout rate and missed visits, may have contributed to the unfavorable outcomes.
Read more →ANIK▲ +6.2%on this news
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. on behalf of its stockholders. This comes after Anika's recent press release regarding the U.S. pivotal clinical trial of Hyalofast, which failed to meet its co-primary endpoints, leading to a significant drop in stock price. The investigation pertains to possible violations of federal securities laws and other business practices. Investors who suffered losses are encouraged to contact the firm for further information.
Read more →ANIKANIKA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Anika Therapeutics, Inc. due to potential violations of federal securities laws. This comes after Anika reported that its pivotal clinical trial for Hyalofast did not meet key objectives, causing a significant drop in the company's stock price. The law firm encourages affected stockholders to discuss their legal rights and options following the trial results and the decline in stock value.
Read more →ANIK▼ -27.4%on this newsshared move
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
Anika Therapeutics announced topline results from its pivotal FastTRACK Phase III study of Hyalofast, a cartilage repair scaffold. While it showed significant improvements in secondary endpoints, it did not meet the primary endpoints for pain and function. The company plans to file the final PMA module by the end of 2025, incorporating additional analyses and data from prior studies.
Read more →ANIK▼ -27.4%on this newsshared move
Anika Reports Second Quarter 2025 Financial Results
Anika Therapeutics reported its second quarter 2025 results, highlighting a 41% increase in Regenerative Solutions revenue primarily driven by the Integrity Implant System. However, financial performance overall saw an 8% revenue decrease compared to Q2 2024, and the Hyalofast clinical trial did not meet its primary endpoints, although it showed positive secondary results. The company maintained its 2025 revenue guidance but adjusted long-term growth expectations due to potential delays in the Hyalofast launch.
Read more →ANIKAnika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025
Anika Therapeutics, Inc. will release its second quarter 2025 financial results on July 30, 2025, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
Read more →ANIKRegenerative Medicine in Orthopedics: Building Stronger Pathways for Healing
The article discusses advancements in orthopedic regenerative medicine, emphasizing the shift from symptom management to biological repair. It highlights innovative technologies such as scaffolds and cellular therapies that promote healing. Anika's products, like Integrity and Hyalofast, are showcased for their roles in enhancing recovery and improving patient outcomes in orthopedic care.
Read more →ANIK▼ -21%on this newsshared move
Anika Reports First Quarter 2025 Financial Results
Anika Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a 10% decrease in total revenue compared to the previous year, despite an 18% increase in its Commercial Channel revenue. Key regulatory milestones were achieved for its products Hyalofast and Cingal, signaling progress for future market launches. Operationally, the company saw a significant reduction in operating expenses by 12%. However, the OEM Channel revenue faced challenges, decreasing by 23%, primarily due to pricing issues.
Read more →ANIKAnika to Participate in the Sidoti Virtual Investor Conference
Anika Therapeutics, Inc. will take part in the Sidoti Virtual Investor Conference on May 21, 2025. The company will host a virtual presentation and Q&A session starting at 1:00 PM ET, which can be accessed through their Investor Relations page. Anika is recognized for its innovations in osteoarthritis pain management and regenerative solutions.
Read more →ANIKAnika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
Anika Therapeutics, Inc. has announced that it will release its financial results for the first quarter of 2025 on May 9, 2025. The release will occur before the market opens, followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Interested parties can access the conference call via telephone or through a live audio webcast available on the company's website. Anika specializes in early intervention orthopedic care, particularly focusing on minimizing arthritic pain and providing regenerative solutions.
Read more →ANIKHydration and Joint Health: Why Water is Your Best Friend
The article emphasizes the critical role of hydration in maintaining joint health. It explains how water contributes to synovial fluid production, cartilage maintenance, and toxin removal, all of which are vital for joint function. Dehydration can lead to increased joint pain and stiffness, making it essential to stay hydrated. The article also suggests incorporating water-rich foods into the diet.
Read more →ANIKAnika Reports Fourth Quarter and Full Year 2024 Financial Results
Anika Therapeutics, Inc. reported its fourth quarter and full year 2024 financial results, indicating a strong performance in its Commercial Channel with a 17% revenue increase year-on-year. The Integrity Implant System recorded over 40% sequential growth, and several key regulatory and clinical milestones were achieved. However, the overall revenue showed a slight decline of 1%, primarily due to lower OEM Channel revenues. Moving forward, Anika's strategic focus on Osteoarthritis Pain Management is expected to enhance its growth trajectory.
Read more →ANIKAnika Completes Divestiture of Parcus Medical
Anika Therapeutics, Inc. has successfully completed the divestiture of its Parcus Medical business to Medacta Group SA. This strategic move is part of Anika's ongoing efforts to focus on its core hyaluronic acid technology and expand its Regenerative Solutions portfolio. The sale was finalized on March 7, 2025, and included customary post-closing adjustments. Anika is committed to ensuring a smooth transition for all stakeholders involved.
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
Anika Therapeutics, Inc. has announced that it will release its fourth quarter and year-end 2024 financial results on March 12, 2025. Following the release, the company will host an investor conference call to discuss the results and business highlights. This demonstrates Anika's commitment to keeping investors informed about its financial performance and strategic direction. Investors can access the call and accompanying materials via the company’s website.
Read more →ANIKAnika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
Anika Therapeutics, Inc. announced that Dr. Cheryl Blanchard, President and CEO, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on March 10, 2025. The company will also engage in one-on-one investor meetings during the event. The presentation will be available via a live webcast and will be archived for 30 days on Anika's website. Anika specializes in joint preservation and early intervention orthopedics, highlighting its innovative products in the field.
Read more →ANIKHeart Healthy Habits for Joint Wellness
The article emphasizes the importance of heart health and its connection to joint wellness. It outlines various heart-healthy habits that also benefit joint health, such as regular exercise, a balanced diet, and stress management. The piece highlights the role of inflammation and circulation in maintaining both heart and joint health. Overall, adopting a holistic approach to wellness can lead to improved quality of life.
Read more →ANIKTop 5 Joint-Friendly Exercises to Start the New Year Strong
The article highlights five joint-friendly exercises ideal for starting the New Year with healthier habits. These exercises, including water walking and yoga, are designed to improve joint mobility and strength while minimizing impact. The piece emphasizes the importance of consulting healthcare providers before beginning new routines, especially for those recovering from surgery or managing joint issues.
Read more →ANIKAnika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
Anika Therapeutics, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. Dr. Cheryl Blanchard, President and CEO, will lead the presentation, and the company will conduct one-on-one investor meetings throughout the event. The presentation will be accessible via a live webcast and archived for 30 days for investor review. Anika focuses on joint preservation and early intervention orthopedic solutions leveraging hyaluronic acid technology.
Read more →ANIKNew Year, Better Sleep: How Quality Rest Can Boost Your Joint Health
The article emphasizes the importance of quality sleep for joint health, particularly as people set health resolutions for the new year. It outlines how restful sleep aids in reducing inflammation, promoting tissue repair, and relieving pain. Tips for improving sleep quality, such as establishing a bedtime routine and creating a sleep-friendly environment, are provided to help individuals achieve better rest and support their joint health.
Read more →ANIKAnika To Participate in December 2024 Investor Conferences
Anika Therapeutics, Inc. will participate in several investor conferences in December 2024, including the Piper Sandler Healthcare Conference, the Sidoti Small-Cap Virtual Conference, and the Benchmark Company's Discovery Conference. Senior management, including CEO Dr. Cheryl Blanchard and CFO Steve Griffin, is scheduled to present at these events and engage in one-on-one meetings with investors. This participation underscores the company's commitment to investor communication and highlights its focus on advancements in orthopedic care.
Read more →ANIKBenefits of Stretching During Travel
The article discusses the importance of incorporating stretching into travel routines to alleviate discomfort from prolonged sitting. It highlights various stretches, such as neck rolls and seated leg extensions, that can enhance flexibility and promote joint health. Additionally, it emphasizes the benefits of travel yoga for relaxation and mental clarity. Overall, stretching is presented as a valuable practice for improving the travel experience.
Read more →ANIK▼ -30.7%on this news
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
Anika Therapeutics has announced the completion of the sale of its Arthrosurface division to Phoenix Brio for $10 million. This decision is part of a strategic review aimed at improving capital allocation to focus on its core products, particularly in hyaluronic acid technology and regenerative solutions. Additionally, Anika plans to pursue the sale of its Parcus Medical business while committing to provide transition support for Arthrosurface until early 2025. The company views these divestitures as a way to enhance shareholder value and streamline operations.
Read more →ANIK▼ -30.7%on this news
Anika Reports Third Quarter 2024 Financial Results
Anika Therapeutics reported a revenue decline of 7% in Q3 2024, primarily driven by challenges in U.S. OA Pain Management. Despite this, the company saw significant growth in its Regenerative Solutions segment and reported a strong performance from its Integrity Implant System. With the recent sale of Arthrosurface and a planned divestiture of Parcus Medical, Anika is strategically refocusing on its core areas for future growth. The company has also updated its long-term financial guidance in light of these restructuring activities.
Read more →ANIKPhysical Therapy: Long-Term Joint Health After Rotator Cuff Surgery
The article discusses the critical role of physical therapy in the recovery process following rotator cuff surgery. It emphasizes that a structured rehabilitation plan is essential for regaining mobility and preventing complications. The collaboration between advanced surgical techniques, like the Integrity Implant, and tailored physical therapy can optimize patient outcomes and promote long-term joint health.
Read more →ANIKAnika Announces Third Quarter 2024 Results Conference Call Date
Anika Therapeutics, Inc. announced the date for its third quarter 2024 financial results, set to be released before the market opens on October 31, 2024. Following the results, a conference call will take place at 8:30 a.m. ET to discuss the company’s financial performance and business updates. Investors can access the call via phone and a webcast will be available on Anika's website, with an archived version accessible soon after.
Read more →ANIKTendon Injuries and Repairs: Cutting-Edge Solutions for Faster Recovery
The article discusses tendon injuries, their causes, and the latest advancements in tendon repair surgery in the US. It highlights the prevalence of tendon injuries and the importance of modern surgical techniques and biologic innovations, such as HA-based implants, in improving recovery outcomes. The shift towards supporting natural healing is emphasized as a significant development in tendon care.
Read more →ANIKAnika Reports Second Quarter 2024 Financial Results
Anika Therapeutics reported its financial results for Q2 2024, highlighting a 5% decrease in total revenue compared to the previous year, affected particularly by a 9% decline in OA Pain Management revenue. Despite this, the company's adjusted EBITDA margins were strong at 15%, and international growth in OA Pain Management was notable with a 17% increase. The full market release of the Integrity Implant System marks a significant development in their Regenerative Solutions portfolio, which the company anticipates will drive future growth. Furthermore, a new $40 million share repurchase program has been launched to enhance shareholder value.
Read more →ANIKDoes Humidity Affect Arthritis and Joint Pain?
The article discusses how humidity, temperature, and barometric pressure can influence arthritis symptoms. High humidity can increase joint pain, while extreme temperatures can cause stiffness and dehydration. It also provides tips for managing arthritis, such as staying active, maintaining a healthy diet, and dressing appropriately for the weather. Understanding these factors can help individuals make informed choices about their living conditions.
Read more →ANIKAnika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Anika Therapeutics, Inc. will release its second quarter 2024 financial results on August 8, 2024, after market close. Following the release, the company will host an investor conference call at 5:00 p.m. ET to discuss these results along with business highlights. Investors can access the call via a dedicated phone line or through a live audio webcast available on Anika's website. The company specializes in joint preservation and aims to provide advancements in orthopedic care.
Read more →ANIKSummer Activities for Staying Active that are Easy on the Joints
The article discusses four summer activities that are gentle on the joints, including biking, trail running, pickleball, and swimming. Each activity is highlighted for its benefits, particularly for individuals with joint pain. The article emphasizes the importance of consulting healthcare providers before starting new exercise routines. Overall, these activities promote fitness and well-being during the summer months.
Read more →ANIKRotator Cuff Repair: The Unabridged Version of What You Can Expect
The article outlines the process and expectations for rotator cuff repair surgery, emphasizing its potential to relieve pain and restore shoulder functionality. It details eligibility criteria for surgery, the evaluation process, and the importance of personalized treatment plans. Additionally, it highlights the role of new technologies like the Integrity™ Implant System in enhancing recovery outcomes.
Read more →ANIKAnika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
Anika Therapeutics announced the full market release of its Integrity Implant System, designed for tendon repairs, particularly in rotator cuff surgeries. The system, which utilizes a hyaluronic acid-based scaffold, aims to enhance healing by providing superior strength and regenerative capacity compared to existing products. Positive feedback from surgeons indicates a successful initial adoption, having completed over 300 surgeries during the limited release. The Integrity Implant System enters a growing market valued at over $190 million, indicating a strong commercial opportunity for Anika.
Read more →ANIKHyaff<sup>®</sup>: Anika’s proprietary breakthrough technology
Anika's Hyaff-11 is a modified form of hyaluronic acid that enhances joint health and tissue repair. It offers longer-lasting effects in the body and supports healing by releasing HA at the implant site. The recently launched Integrity Implant System utilizes this technology for rotator cuff repairs, showcasing Anika's commitment to innovative solutions in regenerative medicine.
Read more →ANIKAnika Enters into Cooperation Agreement with Caligan Partners
Anika Therapeutics, Inc. has entered a cooperation agreement with Caligan Partners, appointing Joseph Capper and William Jellison to its Board of Directors. This move is aimed at enhancing the company's strategic direction and driving shareholder value. In addition to the board changes, Anika has announced a new $40 million share repurchase program. The company's leadership anticipates strong financial performance, projecting $25-$30 million in adjusted EBITDA for 2024, representing significant growth from the previous year.
Read more →ANIKHyaluronic Acid: A Natural Wonder in Rotator Cuff Repair
Anika's Integrity Implant System utilizes hyaluronic acid to enhance rotator cuff repair. The implant, made from a porous, knitted scaffold, supports tissue regeneration and aims to reduce re-tear rates. This innovative application of hyaluronic acid represents a significant advancement in orthopedic surgery, potentially improving patient recovery outcomes.
Read more →ANIKAnika Reports First Quarter 2024 Financial Results
Anika Therapeutics reported a strong start to 2024, with first-quarter revenue of $40.5 million, a 7% increase compared to the previous year. The company has completed its cost reduction initiatives and is on track to meet its adjusted EBITDA guidance of $25-30 million for the year. Despite a net loss of $4.5 million, Anika remains optimistic about its market position and future growth, particularly in Osteoarthritis Pain Management and its innovative HA-based product pipeline. The company's financial health is bolstered by a solid cash balance of $68.6 million.
Read more →ANIKAnika Announces CFO Transition
Anika Therapeutics has announced the appointment of Steve Griffin as the new Chief Financial Officer, effective June 3, 2024. He succeeds Michael Levitz, who will assist in the transition until December 31, 2024. The company is focused on profitability and growth, and Griffin brings over 15 years of financial leadership experience to the role. Anika aims to leverage Griffin's expertise to enhance its operations and advance its product development in orthopedics.
Read more →ANIKAnika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Anika Therapeutics, Inc. announced plans to release its first quarter 2024 financial results following market close on May 8, 2024. The company will conduct an investor conference call at 5:30 p.m. ET the same day to discuss these results and business highlights. Interested participants can access the call through a provided toll-free number or through a live audio webcast available on the company's website. Anika specializes in joint preservation and orthopedic products, contributing to advancements in patient care and minimally invasive solutions.
Read more →ANIKTrail Running: Pros and Cons with Joint Pain
Trail running is gaining popularity among those with joint pain due to its softer surfaces and varied terrain, which can help manage discomfort. The mental health benefits of being in nature also contribute positively. However, potential risks include acute injuries from uneven trails and accessibility challenges for some individuals. Consulting a healthcare professional is recommended before starting.
Read more →ANIKAnika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Anika Therapeutics, Inc. has announced its participation in the 23rd Annual Needham Virtual Healthcare Conference scheduled for April 8, 2024. The event will include a virtual presentation with a Q&A session at 2:15 PM ET. Anika's involvement highlights their role in the orthopedic field and emphasizes their dedication to advancing joint preservation and early intervention solutions.
Read more →ANIKAnika Reports Fourth Quarter and Year-End 2023 Financial Results
Anika Therapeutics reported strong financial results for the fourth quarter and full year ended December 31, 2023, with significant revenue growth in OA Pain Management. The company achieved record annual revenues of $102 million, an 11% increase year-over-year. Despite a substantial non-cash impairment charge affecting net income, Anika expects adjusted EBITDA to rise over 75% in 2024, demonstrating optimism about future profitability and market position. Strategic cost reductions and new product launches are pivotal for the company as it navigates its growth trajectory in 2024.
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
Anika Therapeutics, Inc. announced it will release its fourth quarter and year-end 2023 financial results on March 13, 2024, after market closure. An investor conference call is scheduled for the same day at 5:00 p.m. ET, where financial results and business highlights will be discussed. Anika focuses on advancements in early intervention orthopedics, particularly in areas such as pain management and regenerative solutions. The call will be accessible via phone and live audio webcast, with an archived version available afterward.
Read more →ANIKGive Your Joints Some Love This Winter
The article emphasizes the importance of joint care as winter comes to an end. It provides five key strategies to maintain joint health, including gentle stretching, staying active, applying heat, considering professional massage therapy, and maintaining a nutritious diet. These tips aim to help individuals prepare their joints for the upcoming spring season.
Read more →ANIKReduce Joint Pain One Day at a Time
The article discusses the importance of establishing a routine for individuals suffering from arthritis or joint pain. It suggests breaking down weekly goals into daily tasks to make them more manageable and enjoyable. Each day of the week is dedicated to specific activities, such as stretching, low-impact exercise, and mindful eating, aimed at reducing joint pain. The article emphasizes the value of self-care and healthy habits in improving quality of life.
Read more →ANIKAnika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
Anika Therapeutics, Inc. is showcasing its recently launched products, including the Integrity Implant System and RevoMotion Reverse Shoulder Arthroplasty System, at the 2024 AAOS Annual Meeting. These products focus on enhancing patient outcomes in orthopedic care, particularly in rotator cuff repair. The Integrity Implant System utilizes a hyaluronic acid-based scaffold aimed at promoting healing, while the RevoMotion system includes a new 3-D preoperative planning software named AIM. Anika emphasizes its commitment to providing innovative, minimally invasive solutions for joint preservation and restoration.
Read more →ANIKArthritis-Friendly Gadgets: Navigating the Digital World with Joint Pain
The article discusses the evolution of technology aimed at assisting individuals with arthritis. It highlights various gadgets, including voice-activated assistants, smart home devices, ergonomic accessories, and wearable technology, that help improve daily living for those suffering from joint pain. These innovations empower users to manage their conditions more effectively and enhance their independence.
Read more →ANIK9 Ways to Set (and Keep) Health Intentions for the New Year
The article provides a guide for setting and maintaining health intentions for the New Year. It emphasizes practical, achievable goals such as staying hydrated, prioritizing sleep, and engaging in regular physical activity. The piece encourages readers to adopt a balanced lifestyle while highlighting the importance of consistency and gradual progress.
Read more →ANIK5 Tips for Self-Care During the Most Wonderful (and Stressful) Time of Year
The article emphasizes the importance of self-care, especially during the holiday season, for both mental and physical health. It outlines five practical tips, including establishing a routine, prioritizing sleep, exercising regularly, eating healthily, and setting realistic goals. These practices can help reduce stress and manage conditions like osteoarthritis and osteoporosis.
Read more →ANIKAnika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
Anika Therapeutics, Inc. has successfully performed the first surgeries using its new Integrity Implant System, which is designed for rotator cuff repairs. The FDA-cleared system includes a hyaluronic acid-based scaffold aimed at enhancing tendon healing. With expectations for a full market release in early 2024, the Integrity system is positioned to revolutionize approaches to rotator cuff procedures, backed by positive feedback from surgeons. The U.S. market for rotator cuff augmentation is growing rapidly, underscoring the potential impact of this innovative technology.
Read more →ANIK7 Tips To Minimize Joint Pain This Holiday Season
The article offers seven practical tips for individuals with joint pain to enjoy the holiday season. It emphasizes the importance of anti-inflammatory foods, portion control, and staying active. Additionally, it suggests preparing meals in advance and seeking help from family and friends to reduce stress. These strategies aim to enhance overall well-being during a typically hectic time.
Read more →ANIKAnika to Participate in Upcoming Investor Conferences
Anika Therapeutics, Inc. announced the participation of its CEO Dr. Cheryl Blanchard and CFO Michael Levitz in two upcoming investor conferences. The Stephens Annual Investment Conference will take place on November 15, 2023, followed by participation in the Piper Sandler 35th Annual Healthcare Conference on November 29, 2023. Both events will include live presentations and 1x1 investor meetings, with webcasts available on Anika's website. This engagement emphasizes the company's commitment to investor relations and transparency.
Read more →ANIKAnika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
Anika Therapeutics reported strong third quarter financial results with revenues of $41.5 million, indicating a 3% year-over-year increase. The company has raised its full-year revenue guidance to a range of $164 million to $166 million, attributed to robust growth in Joint Preservation and Restoration. Highlights include the successful launch of the RevoMotion system and FDA approvals for new product lines, expected to boost growth further in 2024. However, the company reported a widening net loss due to project discontinuation and challenges in its Non-Orthopedic segment.
Read more →ANIKOsteoarthritis Is on the Rise – Here’s What Patients Should Know
Osteoarthritis is becoming more prevalent, with predictions indicating nearly 1 billion people will be affected by 2050. Factors contributing to this rise include an aging population, obesity, and population growth. The article provides actionable tips to reduce the risk of developing osteoarthritis, such as staying active, maintaining a healthy diet, and being mindful of mental health.
Read more →ANIKHiking with Grace: How to Conquer the Trails Despite Joint Pain
The article discusses the rising popularity of hiking and its benefits, particularly for those with joint pain or osteoarthritis. It emphasizes the importance of proper footwear, planning, listening to one's body, and staying hydrated while hiking. The piece encourages individuals with joint issues to enjoy hiking by tailoring their approach to their comfort level.
Read more →ANIKAnika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Anika Therapeutics, Inc. plans to release its third quarter 2023 financial results on November 2, 2023, after market closure. The company will also hold an investor conference call at 5:30 p.m. ET on the same day to discuss the results and business highlights. Investors can access the call through a toll-free number, and the audio webcast will be available on Anika's website. This demonstrates the company's commitment to transparency and stakeholder engagement.
Read more →ANIKRecovering Strong: A Guide to Rotator Cuff Surgery and What You Can Expect
Rotator cuff tears are common among older adults, often requiring surgery. Most procedures are outpatient, allowing same-day recovery. Post-surgery, patients must follow care instructions, including using a sling and managing pain. Recovery can take 4-6 months, with gradual return to activities. Assistance from friends and family is recommended during recovery.
Read more →ANIKAnika.
Anika Holdings is expanding its portfolio with multiple new product launches targeting the joint preservation market, including the RevoMotion Reverse Shoulder System and the X-Twist Fixation System. These initiatives are supported by robust cash flow generation, and early surgeon feedback on the new products has been highly positive. Anika is also continuing to engage with the FDA on their pipeline projects, including the Hyalofast and Cingal products. The company aims to maintain growth momentum with a focus on market expansion and operational efficiency.
Read more →ANIKAnika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
Anika Therapeutics has officially launched the RevoMotion Reverse Shoulder Arthroplasty System at the 2023 Orthopaedic Summit Annual Meeting, expanding their shoulder arthroplasty offerings. The system is designed for bone conservation and integrates various humeral tray sizes for personalized treatment. Surgeons have provided positive feedback during its limited market release, indicating enhanced patient satisfaction and improved outcomes. Anika will also showcase the recently cleared Integrity regenerative HA-based patch system at this event.
Read more →ANIKAnika to Participate in the Sidoti Small Cap Virtual Investor Conference
Anika Therapeutics, Inc. has announced its participation in the Sidoti Small Cap Virtual Investor Conference set for September 21, 2023. The management will host a virtual presentation followed by a Q&A session at 10:45 AM ET. This initiative highlights Anika's commitment to transparency and investor relations while showcasing its advancements in orthopedic care, specifically in joint preservation.
Read more →ANIKPlaying Pickleball: Strategies for Shoulder Health and Injury Awareness
Pickleball is gaining immense popularity in the U.S., with an expected player base of over 22 million by year-end. However, this surge brings a projected $377 million in healthcare costs due to injuries. Common injuries include shoulder pain and strains, but adopting preventative strategies can help mitigate risks. Resources like Anika's shoulder solutions are available for recovery.
Read more →ANIKAnika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
Anika Therapeutics has obtained FDA 510(k) clearance for its Integrity™ Implant System, a regenerative patch designed for rotator cuff repairs. This innovation enhances the company's product offerings in the orthopedic market, specifically targeting the $150 million rotator cuff augmentation sector. The Integrity system is anticipated to be launched in the first quarter of 2024, and its advanced design is expected to improve patient outcomes through better tendon healing. Anika aims to expand this technology further into various anatomical applications following its initial release.
Read more →ANIKAnika Reports Second Quarter 2023 Financial Results
Anika Therapeutics reported a strong second quarter for 2023, showcasing a 12% increase in revenue driven by significant growth in OA Pain Management. The company has successfully enrolled its pivotal Phase III clinical trial for Hyalofast, and is planning to commence its modular PMA submission in 2024. However, Anika also reported a net loss of $2.7 million during the quarter, and faced a substantial 33% decline in revenue from its Non-Orthopedic segment. The company remains optimistic about its revenue outlook for the remainder of 2023.
Read more →ANIKStaying Active With Osteoporosis: 6 Tips To Exercise Safely
The article discusses osteoporosis, a condition affecting millions globally, and emphasizes the importance of regular exercise for those diagnosed. It provides six practical tips for safely exercising with osteoporosis, including starting slow, engaging in brisk walking, and following a diverse exercise routine. The article also advises avoiding high-impact activities and consulting healthcare providers for personalized guidance.
Read more →ANIKAnika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Anika Therapeutics, Inc. plans to release its financial results for the second quarter of 2023 on August 8, 2023, following the market's close. The company will also hold an investor conference call at 5:00 p.m. ET to discuss these results and share business highlights. Investors can access the call through a dial-in number or via a live audio webcast on Anika's website. The conference will be archived for later access.
Read more →ANIKAnika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
Anika Therapeutics, Inc. highlighted its advanced joint preservation products at the 2023 AOSSM Annual Meeting. Key offerings included the award-winning Tactoset Injectable Bone Substitute and the new X-Twist Fixation System. The Tactoset received notable recognition for its innovative approach in augmenting hardware for surgical applications. Anika is set to address ongoing needs in sports medicine and share clinical outcomes related to its products at the conference.
Read more →ANIKAnika Completes Enrollment in Hyalofast U.S. Pivotal Phase III Study Achieving Key Milestone
Anika Therapeutics announced the completion of enrollment in the pivotal Phase III clinical study for its cartilage repair product, Hyalofast. The FDA has designated Hyalofast as a Breakthrough Device, which allows prioritized engagement and review during the premarket approval process. Anika plans to submit a modular PMA application beginning in 2024. Outside the U.S., Hyalofast has been shown to be safe and effective for cartilage repair for over ten years, creating optimism for its market entry. The product aims to revolutionize knee cartilage repair by eliminating the need for a second surgery.
Read more →ANIKAnika Reports First Quarter 2023 Financial Results
Anika Therapeutics reported its financial results for the first quarter of 2023, revealing a 3% increase in revenue compared to the previous year, totaling $37.9 million. The company experienced significant growth in its Joint Preservation and Restoration product family and OA Pain Management, although it also reported a larger net loss of ($10.4) million. The fiscal outlook for 2023 anticipates overall revenue growth between 1% and 4%, despite challenges presented by a decrease in Non-Orthopedic revenues. Anika's management expressed confidence in their market position and upcoming product releases.
Read more →ANIKAnika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
Anika Therapeutics, Inc. (NASDAQ: ANIK) has announced it will release its first quarter 2023 financial results on May 9, 2023, after market close. The company will hold an investor conference call at 5:00 p.m. ET on the same day to discuss these results and provide business insights. Anika operates in the orthopedic sector, focusing on joint preservation and minimally invasive products for various conditions.
Read more →ANIKAnika Enters Into Cooperation Agreement with Caligan Partners Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee Bedford, Mass.
Anika Therapeutics, Inc. has entered into a cooperation agreement with Caligan Partners, leading to the appointment of Gary Fischetti as a Class III director on the Board. The company has also launched a $20 million share repurchase program to return capital to shareholders and has formed a Capital Allocation Committee to strategically review its investments. This move signifies Anika's commitment to enhance shareholder value and pursue growth, supported by Fischetti's extensive experience in the medical device industry. The changes come ahead of the company's 2023 Annual Meeting of Stockholders.
Read more →ANIKAnika to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Anika Therapeutics, Inc. will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023. The company's management will host a virtual presentation along with a Q&A session. This event aims to highlight Anika's advancements in early intervention orthopedic care and their focus on minimally invasive products.
Read more →ANIKAnika Continues to Expand Addressable Market for Tactoset Injectable Bone Substitute with Additional 510(k) Clearance from FDA
Anika Therapeutics announced the FDA's additional 510(k) clearance for its Tactoset Injectable Bone Substitute, allowing it to be used with autologous bone marrow aspirate (BMA), which is expected to improve healing in difficult cases. Alongside this, Anika has signed a distribution agreement for the Marrow Cellution Bone Marrow Aspiration Needle to enhance product efficiency and has launched enhanced delivery cannulas for better usability in foot and ankle procedures. These advancements are poised to significantly expand Tactoset's commercial reach and address unmet needs in the orthopedic market.
Read more →ANIKAnika Files Preliminary Proxy Statement
Anika Therapeutics has filed preliminary proxy materials for its upcoming 2023 Annual Meeting of Stockholders. The company recommends re-electing two board nominees as part of its ongoing board refreshment initiative. Anika has made significant transformations in its market positioning, expanding its opportunity significantly. However, a shareholder, Caligan Partners LP, has proposed alternative candidates and plans to push for strategic changes that the Board believes may threaten shareholder value.
Read more →ANIKAnika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting
Anika Therapeutics showcased its latest products at the 2023 AAOS Annual Meeting, emphasizing the X-Twist Fixation System, RevoMotion Reverse Shoulder Arthroplasty System, and OVOMotion with Inlay Glenoid TSA System. The presentation underscored Anika's commitment to addressing evolving needs in joint preservation and restoration. With the emphasis on innovation, particularly the RevoMotion system, Anika aims to enhance surgical techniques and patient outcomes in orthopedic care. Opportunities for further insights into the products will be available during theater sessions at the event.
Read more →ANIK▼ -8.6%on this newsshared move
Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results
Anika Therapeutics (NASDAQ: ANIK) reported financial results for the fourth quarter and full year ending December 31, 2022, highlighting revenue growth of 11% in Q4 and 6% for the year. The company initiated the limited market release of its RevoMotion Reverse Shoulder Arthroplasty System and achieved improved operational performance in its OA Pain Management sector. Despite a net loss reported for the quarter, Anika remains optimistic about the upcoming fiscal year, projecting revenue growth driven by key product advancements. The company's Hyalofast product has been designated as a Breakthrough Device by the FDA, reinforcing its commitment to innovation.
Read more →ANIKAnika to Participate in the Canaccord Genuity Musculoskeletal Conference
Anika Therapeutics, Inc. announced its participation in the Canaccord Genuity Musculoskeletal Conference in Las Vegas, scheduled for March 7, 2023. The event highlights the company's commitment to advancing joint preservation and orthopedic care. A live webcast will be available for investors, showcasing Anika's innovative approach in minimally invasive treatments for managing osteoarthritis and other orthopedic needs.
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023
Anika Therapeutics, Inc. will announce its fourth quarter and year-end 2022 financial results on March 6, 2023. The company will host an investor conference call the same day to discuss these results and business highlights. Their focus remains on joint preservation and innovative orthopedic solutions, positioning them as a key player in the healthcare sector. Investors will have access to a live audio webcast and a slide presentation on the company's website.
Read more →ANIKAnika Issues Statement
Anika Therapeutics, Inc. has issued a statement addressing queries from Caligan Partners LP, highlighting its growth strategy in joint preservation. The company has made progress in expanding its market presence and aims to grow its opportunities significantly. Anika's stock price has risen by around 40% since June 2022, outpacing the NASDAQ Composite Index. The company will soon release its fourth quarter financial results and is optimistic about future product launches and shareholder value creation.
Read more →ANIKAnika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States
Anika Therapeutics has announced the limited market release of its RevoMotion Reverse Shoulder Arthroplasty System, marking its entry into the rapidly growing U.S. reverse shoulder market. The system is noted for its small diameter threaded glenoid baseplate, which aims to enhance surgical efficiency and preserve bone. Surgeons have begun performing surgeries with RevoMotion and reported positive experiences with its design. Anika anticipates a full market release later in 2023, further expanding its offerings in joint preservation and orthopedics.
Read more →ANIK▼ -7.3%on this news
Anika Reports Third Quarter Fiscal 2022 Financial Results
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-Stage Cartilage R
Read more →ANIK▲ +5.7%on this news
Anika’s Cingal Successfully Achieves Primary Endpoint in Third Phase III Study
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Plac
Read more →ANIK▲ +5%on this news
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market
Read more →ANIKAnika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release
BEDFORD, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the limited market release and the first surgeries performed using the X-Twist Fixation Syste
Read more →ANIKAnika Reports Second Quarter Fiscal 2022 Financial Results
Second quarter revenue growth up 4% X-Twist™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedic
Read more →ANIKAnika Receives the ACE Award for Cutting-Edge Innovation for Tactoset Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaed
Read more →ANIKAnika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022
BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2022 financial results after the close of the marke
Read more →ANIKAnika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio
BEDFORD, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the
Read more →ANIKAnika to Participate in the UBS Global Healthcare Conference 2022
BEDFORD, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the UBS Global Healthcare Conference 2022 being held in-person at t
Read more →ANIK▼ -7%on this newsshared move
Anika Reports First Quarter Fiscal 2022 Financial Results
BEDFORD, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2022. First Quarter 2022 Financial Summary Rev
Read more →ANIKAnika to Issue First Quarter 2022 Financial Results on Thursday, May 5, 2022
BEDFORD, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2022 financial results after the close of the marke
Read more →ANIKAnika to Participate in the 21st Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday
Read more →ANIKAnika to Showcase its Transformation into a Global Leader in Joint Preservation during the 2022 AAOS Annual Meeting
BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced it will showcase its comprehensive joint preservation and restoration product portfolio at the 2022 American Academy of Orthopedic Surg
Read more →ANIKAnika Reports Fourth Quarter and Year-End 2021 Financial Results
Fourth quarter revenue growth of 10% year-over-year despite COVID headwinds Full-year 2021 revenue up 13% driven by strong growth in Joint Preservation and Restoration BEDFORD, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint pre
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2021 financial results after the close
Read more →ANIKAnika Reports Third Quarter 2021 Financial Results
Revenue growth of 25% year-over-year Company revises revenue growth outlook for 2021 to 9-11% on COVID Delta headwinds BEDFORD, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedic
Read more →ANIKAnika Appoints Sheryl Conley to Board of Directors
BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective Oct
Read more →ANIKAnika to Issue Third Quarter 2021 Financial Results on Thursday, November 4, 2021
BEDFORD, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2021 financial results after the close of the market
Read more →ANIKAnika Launches the WristMotion Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting
BEDFORD, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced its WristMotion® Total Wrist Arthroplasty (TWA) System was launched at the American Society for Surgery of the Hand (ASSH) 2021 annual
Read more →ANIKAnika to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
BEDFORD, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executiv
Read more →ANIKAnika to Debut Joint Preservation Portfolio at the 2021 AAOS Annual Meeting
BEDFORD, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, will debut their full joint preservation and restoration product portfolio at the 2021 American Academy of Or
Read more →ANIKAnika Reports Second Quarter 2021 Financial Results
Revenue growth of 24% year-over-year Company raises full year revenue growth outlook to 11-14% BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financ
Read more →ANIKAnika to Issue Second Quarter 2021 Financial Results on Thursday, August 5, 2021
BEDFORD, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2021 financial results after the close of the marke
Read more →ANIKAnika Hosts 2021 Virtual Investor Day
Company details multi-year Joint Preservation strategy for accelerated revenue growth and profitability Updates 2021 directional outlook and 2024 multi-year targets BEDFORD, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preserv
Read more →ANIKAnika to Host its 2021 Virtual Investor Day on June 3, 2021
BEDFORD, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:0
Read more →ANIKAnika Reports First Quarter 2021 Financial Results
Revenue lower by 3% versus pre-COVID in prior year Joint Preservation revenue up 55% as transformative mix shift continues Company on track to achieve stated revenue growth in 2021 BEDFORD, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a glob
Read more →ANIKAnika to Participate in Upcoming Virtual Investor Conferences
BEDFORD, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice Pre
Read more →ANIKAnika to Issue First Quarter 2021 Financial Results on Thursday, May 6, 2021
BEDFORD, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2021 financial results after the close of the marke
Read more →ANIKAnika to Participate in the 20th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice P
Read more →ANIKAnika to Participate in the Sidoti Spring Virtual Investor Conference
BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice P
Read more →ANIKAnika Reports Fourth Quarter and Year-End 2020 Financial Results
Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021 BEDFORD, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creat
Read more →ANIKAnika to Issue Fourth Quarter and Year-End 2020 Financial Results on Thursday, March 4, 2021
BEDFORD, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quart
Read more →ANIKAnika Reports Third-Quarter 2020 Financial Results
Revenue Increased 7% Year-over-Year to $31.7 Million Repaid $25 Million of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio BEDFORD, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preserva
Read more →ANIKAnika to Issue Third Quarter 2020 Financial Results and Business Highlights on Wednesday, November 4, 2020
BEDFORD, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its third quarte
Read more →ANIKAnika Announces FDA 510(k) Clearance for its WristMotion Total Arthroplasty System for the Replacement of Painful Wrist Joints
BEDFORD, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company’s WristMotion Total Arthroplast
Read more →ANIKAnika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
Board Chair Joseph Bower, D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board BEDFORD, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated jo
Read more →ANIKAnika Appoints Michael Levitz as Chief Financial Officer
BEDFORD, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced the appoint
Read more →ANIKAnika Reports Second Quarter 2020 Financial Results
Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020 BEDFORD, Mass., July 30, 2020 (GLOBE NEWSWIRE
Read more →ANIKAnika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020
BEDFORD, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced U.S. Food a
Read more →ANIKAnika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
BEDFORD, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Co
Read more →ANIKAnika Announces Planned CFO Transition
Sylvia Cheung to Step Down in August 2020 Company Initiates Search for Successor BEDFORD, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products across the orthop
Read more →ANIKAnika Reports First Quarter 2020 Financial Results
Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage through COVID-19 Pandemic BEDFORD, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Ani
Read more →ANIKAnika Takes Actions to Strengthen Liquidity in Light of COVID-19
BEDFORD, Mass., April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform, today provided an update on
Read more →ANIKAnika Reports Fourth Quarter and Full Year 2019 Financial Results
Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, I
Read more →ANIKAnika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
BEDFORD, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Bo
Read more →ANIKAnika Therapeutics Closes Acquisition of Arthrosurface
BEDFORD, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has complete
Read more →ANIKAnika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer
BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62. “We are shock
Read more →ANIKAnika Therapeutics Closes Acquisition of Parcus Medical
BEDFORD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it has closed i
Read more →ANIKAnika Therapeutics to Acquire Parcus Medical and Arthrosurface Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Con
Anika Therapeutics to Acquire Parcus Medical and Arthrosurface Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Conference Call & Webcast January 8 at 8:30 a.m. ET BEDFORD,
Read more →ANIKAnika Reports Third Quarter 2019 Financial Results Total Revenue Increases 11% and Net Income Increases 21% Year-over-Year Company Raises Full Year 2019 Revenue and Earnings Guidance Executing Five-Year Strategic Plan Fo
Anika Reports Third Quarter 2019 Financial Results Total Revenue Increases 11% and Net Income Increases 21% Year-over-Year Company Raises Full Year 2019 Revenue and Earnings Guidance Executing Five-Year Strategic Plan Focused on Joint Preservation and Restoration BEDFORD, Mas
Read more →ANIKAnika Reports Second Quarter 2019 Financial Results Delivers Strong Bottom Line Performance with $0.67 Diluted EPS CINGAL Revenue Drives International Viscosupplement Revenue Growth of 28% Year-over-Year Announces Decisi
Anika Reports Second Quarter 2019 Financial Results Delivers Strong Bottom Line Performance with $0.67 Diluted EPS CINGAL Revenue Drives International Viscosupplement Revenue Growth of 28% Year-over-Year Announces Decision to Advance CINGAL Program Towards U.S. Regulatory Appr
Read more →ANIKAnika Reports First Quarter 2019 Financial Results Total Revenue Increased 16% Year-over-Year Solid Bottom Line Performance with $0.31 Diluted EPS New Leadership Added to Accelerate Innovation and Expand Commercial Reach
Reports First Quarter 2019 Financial Results Revenue Increased 16% Year-over-Year Bottom Line Performance with $0.31 Diluted EPS Leadership Added to Accelerate Innovation and Expand Commercial Reach $50 Million Share Repurchase Program BEDFORD, Mass.--(BUSINESS WIRE)--May 2,
Read more →ANIKAnika Reports Fourth Quarter and Full Year 2018 Financial Results Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018 MONOVISC and CINGAL Global Revenue Increased 14% for Full Year of 2018 BE
Reports Fourth Quarter and Full Year 2018 Financial Results Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018 and CINGAL Global Revenue Increased 14% for Full Year of 2018 BEDFORD, Mass.--(BUSINESS WIRE)--February 21, 2019--Anika Therapeutics, Inc. (NA
Read more →ANIKAnika Reports Third Quarter 2018 Financial Results CINGAL Drives Strong International Viscosupplement Revenue Growth Achieves Solid Bottom Line Performance with $0.53 Diluted EPS BEDFORD, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2018 Financial Results Drives Strong International Viscosupplement Revenue Growth Solid Bottom Line Performance with $0.53 Diluted EPS BEDFORD, Mass.--(BUSINESS WIRE)--October 24, 2018--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthop
Read more →ANIKAnika Reports Second Quarter 2018 Financial Results Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS New Leadership Added to Optimize Commercial Reach and Operating Efficiency Mu
Reports Second Quarter 2018 Financial Results Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Leadership Added to Optimize Commercial Reach and Operating Efficiency Initiatives Ongoing to Gain U.S. Regulatory Approval of CINGAL BEDFORD, Mass.--(BUSINE
Read more →ANIKAnika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study
Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. a
Read more →ANIKAnika Reports First Quarter 2018 Financial Results Successful Leadership Transition in Evolution to a Global Commercial Organization; MONOVISC and CINGAL Global Revenue Increased 38% Year-over-Year; Initiated Voluntary R
Reports First Quarter 2018 Financial Results Leadership Transition in Evolution to a Global Commercial Organization; and CINGAL Global Revenue Increased 38% Year-over-Year; Voluntary Recall of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX BEDFORD, Mass.--(BUSINESS WIRE)--May 2, 201
Read more →ANIKAnika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
BEDFORD, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase its innovative
Read more →ANIKAnika Reports Fourth Quarter and Full Year 2017 Financial Results MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass.--(BUSINE
Reports Fourth Quarter and Full Year 2017 Financial Results Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass.--(BUSINESS WIRE)--February 21, 2018--Anika Therapeutics, Inc. (NASDAQ: ANIK), a globa
Read more →ANIKAnika Reports Third Quarter 2017 Financial Results Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BU
Reports Third Quarter 2017 Financial Results Enrollment in CINGAL Phase III Clinical Trial; of Regenerative Medicine Pipeline; Revenue Increased 50% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)--October 25, 2017--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrate
Read more →ANIKAnika Announces Appointment of Joseph Darling as President Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass.--(BUSINESS WIRE)
Anika Announces Appointment of Joseph Darling as President Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass.--(BUSINESS WIRE)--July 27, 2017--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specia
Read more →ANIKAnika Reports Strong Second Quarter 2017 Financial Results MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass.--(BUSINESS W
Anika Reports Strong Second Quarter 2017 Financial Results MONOVISC U.S. End-User Sales Exceeded $100 Million at an Accelerated Pace CINGAL Phase III Clinical Trial Achieved Rapid Advancements BEDFORD, Mass.--(BUSINESS WIRE)--July 26, 2017--Anika Therapeutics, Inc. (NASDAQ: AN
Read more →ANIKAnika Reports First Quarter 2017 Financial Results
MONOVISC Revenue Increases 24% Year-over-Year Total Revenue Grows 5% Year-over-Year Commercially Launches ORTHOVISC-T in Europe BEDFORD, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedic medicines company specializi
Read more →ANIKAnika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc., (Nasdaq:ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid "HA" technology, will visit the Nasdaq MarketSite in Times Square in celeb
Read more →ANIKAnika Reports Fourth Quarter and Full Year 2016 Financial Results Worldwide Orthobiologics Revenue Increases 13% Year-over-Year for Fourth Quarter of 2016 Product Revenue Grows 17% for Full Year of 2016 BEDFORD, Mass.--(
Reports Fourth Quarter and Full Year 2016 Financial Results Orthobiologics Revenue Increases 13% Year-over-Year for Fourth Quarter Revenue Grows 17% for Full Year of 2016 BEDFORD, Mass.--(BUSINESS WIRE)--February 15, 2017--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, in
Read more →ANIKAnika Reports Third Quarter 2016 Financial Results Worldwide Orthobiologics Revenue Increases 10% Year-over-Year Diluted Earnings Per Share Increases to $0.59 BEDFORD, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2016 Financial Results Orthobiologics Revenue Increases 10% Year-over-Year Earnings Per Share Increases to $0.59 BEDFORD, Mass.--(BUSINESS WIRE)--October 26, 2016--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company
Read more →ANIKAnika Reports Second Quarter 2016 Financial Results Total Revenue Increases 16% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2016 Financial Results Revenue Increases 16% Year-over-Year BEDFORD, Mass.--(BUSINESS WIRE)--July 27, 2016--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary
Read more →ANIKAnika Reports First Quarter 2016 Financial Results Total Revenue Increased 44% Year-over-Year Commenced $25 million Accelerated Share Repurchase Program BEDFORD, Mass.--(BUSINESS WIRE)
Reports First Quarter 2016 Financial Results Revenue Increased 44% Year-over-Year $25 million Accelerated Share Repurchase Program BEDFORD, Mass.--(BUSINESS WIRE)--April 27, 2016--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company spec
Read more →ANIKAnika Therapeutics Delivers Strong Performance with Record Product Revenue for the Fourth Quarter and Full Year 2015 Product Revenue Increased 43% Year-over-Year for Fourth Quarter of 2015 BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Delivers Strong Performance with Record Product Revenue for the Fourth Quarter and Full Year 2015 Revenue Increased 43% Year-over-Year for Fourth Quarter of 2015 BEDFORD, Mass.--(BUSINESS WIRE)--February 24, 2016--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global
Read more →ANIKAnika Therapeutics Announces Decision to Proceed with CINGAL Premarket Review Through FDA's Center for Drug Evaluation and Research BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Announces Decision to Proceed with CINGAL Premarket Review Through FDA's Center for Drug Evaluation and Research BEDFORD, Mass.--(BUSINESS WIRE)--December 9, 2015--Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specia
Read more →ANIKAnika Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015 Company Achieves 37.5% Year-over-Year Diluted EPS Growth in Quarter BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports Robust Financial Performance and Continued Progress on Key Fronts in Third Quarter of 2015 Achieves 37.5% Year-over-Year Diluted EPS Growth in Quarter BEDFORD, Mass.--(BUSINESS WIRE)--October 28, 2015--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, in
Read more →ANIKAnika Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline Progress Strength in Quarter Driven by Continued Adoption of Orthobiologics Products; Combined ORTHOVISC and MONOVISC U.S. Ma
Therapeutics Delivers Solid Second Quarter 2015 Financial Results and Continued Pipeline Progress in Quarter Driven by Continued Adoption of Orthobiologics Products; ORTHOVISC and MONOVISC U.S. Market Share Surpasses 25% BEDFORD, Mass.--(BUSINESS WIRE)--July 29, 2015--Anika T
Read more →ANIKAnika Therapeutics Reports Fourth-Quarter and Full-Year 2014 Financial Results Monovisc Receives Unique J-Code Assignment from CMS Effective
Therapeutics Reports Fourth-Quarter and Full-Year 2014 Financial Results Receives Unique J-Code Assignment from CMS Effective January 1, 2015 Revenue for 2014 Increases 41% to a Record $106 Million with Net Income BEDFORD, Mass.--(BUSINESS WIRE)--February 25, 2015--Anika Thera
Read more →ANIKAnika Therapeutics Appoints Dr. Glenn Larsen to its Board of Directors BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Appoints Dr. Glenn Larsen to its Board of Directors BEDFORD, Mass.--(BUSINESS WIRE)--February 19, 2015--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has appointed Glenn R. Larsen, Ph.D., as a new independent member of its Board of Directors. Dr
Read more →ANIKAnika Therapeutics Reports Third-Quarter 2014 Financial Results Third-Quarter Total Revenue Grows 24% to $22.1 Million Earnings per Share Increase to $0.40 from $0.33 BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports Third-Quarter 2014 Financial Results Total Revenue Grows 24% to $22.1 Million per Share Increase to $0.40 from $0.33 BEDFORD, Mass.--(BUSINESS WIRE)--October 29, 2014--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, he
Read more →ANIKAnika Therapeutics Reports Second-Quarter 2014 Financial Results Total Revenue Grows 26% to $26.3 Million Commercial Launch of Monovisc Generates $5 Million Milestone Payment Earnings per Share Increase to $0.60 from $0.
Therapeutics Reports Second-Quarter 2014 Financial Results Revenue Grows 26% to $26.3 Million Generates $5 Million Milestone Payment per Share Increase to $0.60 from $0.40 a Year Earlier BEDFORD, Mass.--(BUSINESS WIRE)--July 30, 2014--Anika Therapeutics, Inc. (Nasdaq: ANIK),
Read more →ANIKAnika Therapeutics Reports First Quarter 2014 Financial Results Receives $17.5 Million in Monovisc Milestone Payment Total Revenue Grows 123% to $34 Million Earnings per Share Increase to $0.97 from $0.21 a Year Earlier
Therapeutics Reports First Quarter 2014 Financial Results $17.5 Million in Monovisc Revenue Grows 123% to $34 Million per Share Increase to $0.97 from $0.21 a Year Earlier BEDFORD, Mass.--(BUSINESS WIRE)--April 29, 2014--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in p
Read more →ANIKAnika Therapeutics Announces Dismissal of MONOVISC U.S. Patent Infringement Lawsuit BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Announces Dismissal of MONOVISC U.S. Patent Infringement Lawsuit BEDFORD, Mass.--(BUSINESS WIRE)--March 13, 2014--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology,
Read more →ANIKAnika Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Monovisc Achieves FDA Approval EPS Increases 42% to $0.44 in Quarter and 70% to $1.39 for Year Cingal TM Phase III Clinical Trial Enrollment
Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Achieves FDA Approval Increases 42% to $0.44 in Quarter and 70% to $1.39 for Year Phase III Clinical Trial Enrollment Complete Revenue for 2013 Grows to $75.1 Million BEDFORD, Mass.--(BUSINESS WIRE)--Fe
Read more →ANIKAnika Therapeutics Reports 20% Total Revenue Growth and Record Third-Quarter Earnings Total Revenue Grows to $17.8 Million Net Income Rises to $5.0 Million and EPS Increase to $0.33 BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 20% Total Revenue Growth and Record Third-Quarter Revenue Grows to $17.8 Million Income Rises to $5.0 Million and EPS Increase to $0.33 BEDFORD, Mass.--(BUSINESS WIRE)--October 30, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for ti
Read more →ANIKAnika Therapeutics Appoints Industry-Recognized R&D Executive John W. Sheets, Jr., Ph.D. as Chief Scientific Officer Anika Also Announces Resignation of COO Frank Luppino BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Appoints Industry-Recognized R&D Executive John W. Sheets, Jr., Ph.D. as Chief Scientific Officer Also Announces Resignation of COO Frank Luppino BEDFORD, Mass.--(BUSINESS WIRE)--October 2, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for t
Read more →ANIKAnika Therapeutics Reports Record Second-Quarter Revenue and Earnings Net Income Grows 58% and EPS Rise to $0.40 Cingal TM Phase III Osteoarthritis Clinical Study in Active Patient Recruitment Stage BEDFORD, Mass.--(BUSI
Therapeutics Reports Record Second-Quarter Revenue and Earnings Income Grows 58% and EPS Rise to $0.40 Phase III Osteoarthritis Clinical Study in Active Patient Recruitment BEDFORD, Mass.--(BUSINESS WIRE)--July 31, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in pr
Read more →ANIKAnika Therapeutics Reports First-Quarter 2013 Financial Results Achieves Net Income Growth of 60%, Earnings Per Share of $0.21, and Cash Generated from Operations of $6 Million for the Quarter BEDFORD, Mass.--(BUSINESS W
Therapeutics Reports First-Quarter 2013 Financial Results Net Income Growth of 60%, Earnings Per Share of $0.21, and Cash Generated from Operations of $6 Million for the Quarter BEDFORD, Mass.--(BUSINESS WIRE)--May 1, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in
Read more →ANIKAnika Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results Fourth Quarter Revenue Increases 23% on Strong Sales of Orthovisc Earnings Grow 48% to $0.31 per Share in Quarter and 32% to $0.82 per Share
Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results Quarter Revenue Increases 23% on Strong Sales of Orthovisc Grow 48% to $0.31 per Share in Quarter and 32% to $0.82 per Share for BEDFORD, Mass.--(BUSINESS WIRE)--February 27, 2013--Anika Therapeutics, In
Read more →ANIKAnika Therapeutics Names Sylvia Cheung as Chief Financial Officer Provides Summary of Fourth Quarter and 2012 Preliminary Financial Results BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Names Sylvia Cheung as Chief Financial Officer Summary of Fourth Quarter and 2012 Preliminary Financial Results BEDFORD, Mass.--(BUSINESS WIRE)--January 22, 2013--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced the appointment of Sylvia Cheung as the comp
Read more →ANIKAnika Therapeutics Announces Monovisc PMA News BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Announces Monovisc PMA News BEDFORD, Mass.--(BUSINESS WIRE)--December 4, 2012--Anika Therapeutics, Inc. (Nasdaq: ANIK) announced today that it has received correspondence from the Chief Scientific Officer of the Center for Devices and Radiological Health of the U
Read more →ANIKAnika Therapeutics Reports Third-Quarter Financial Results Achieves Revenue of $14.8 Million, Earnings per Share of $0.11 and Cash Generated from Operations of $2.2 Million for the Quarter Reports on FDA Progress with Mo
Therapeutics Reports Third-Quarter Financial Results Revenue of $14.8 Million, Earnings per Share of $0.11 and Cash Generated from Operations of $2.2 Million for the Quarter on FDA Progress with Monovisc BEDFORD, Mass.--(BUSINESS WIRE)--October 30, 2012--Anika Therapeutics,
Read more →ANIKAnika Therapeutics Reports Record Second Quarter Revenue and Earnings Total Revenue Grows 22%; Earnings Increase 53% to $0.26 per Share BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports Record Second Quarter Revenue and Earnings Revenue Grows 22%; Earnings Increase 53% to $0.26 per Share BEDFORD, Mass.--(BUSINESS WIRE)--August 1, 2012--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repai
Read more →ANIKAnika Therapeutics Reports Record First-Quarter Revenue and Earnings Total Revenue Grows 22% and Earnings Increase to $0.14 per Share BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports Record First-Quarter Revenue and Earnings Revenue Grows 22% and Earnings Increase to $0.14 per Share BEDFORD, Mass.--(BUSINESS WIRE)--May 3, 2012--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair, ba
Read more →ANIKAnika Therapeutics Reports 25% Increase in Fourth-Quarter Revenue Earnings More Than Double to 21 per Share Anika S.r.l. Achieves Breakeven Operations for Fourth Quarter BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 25% Increase in Fourth-Quarter Revenue More Than Double to 21 per Share S.r.l. Achieves Breakeven Operations for Fourth Quarter BEDFORD, Mass.--(BUSINESS WIRE)--February 29, 2012--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue pr
Read more →ANIKAnika Therapeutics Announces U.S. MONOVISC License and Supply Agreement with DePuy Mitek, Inc. BEDFORD, Mass.--(BUSINESS WIRE)
Anika Therapeutics Announces U.S. MONOVISC License and Supply Agreement with DePuy Mitek, Inc. BEDFORD, Mass.--(BUSINESS WIRE)--December 21, 2011--Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced the signing of an exclusive, multi-year U.S. licensing and supply agreement w
Read more →ANIKAnika Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 Earnings per share grow 144% to 22 Orthobiologics product revenue rises 35%, driven by growing Orthovisc sales BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 33% Revenue Growth in Third Quarter 2011 per share grow 144% to 22 product revenue rises 35%, driven by growing Orthovisc BEDFORD, Mass.--(BUSINESS WIRE)--November 2, 2011--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protectio
Read more →ANIKAnika Therapeutics Reports Second-Quarter 2011 Financial Results Second Quarter and six-month EPS increase 112% and 45%, respectively U.S. sales of Orthovisc drive 27% growth in Q2 orthobiologics revenue BEDFORD, Mass.--
Therapeutics Reports Second-Quarter 2011 Financial Results Quarter and six-month EPS increase 112% and 45%, respectively drive 27% growth in Q2 orthobiologics revenue BEDFORD, Mass.--(BUSINESS WIRE)--August 4, 2011--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in product
Read more →ANIKAnika Therapeutics Reports First-Quarter 2011 Financial Results Orthobiologics Revenue Rises 16% Anika S.r.l. Product Sales Grow 22% BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports First-Quarter 2011 Financial Results S.r.l. Product Sales Grow 22% BEDFORD, Mass.--(BUSINESS WIRE)--May 4, 2011--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and repair, based on hyaluronic acid ("HA") tech
Read more →ANIKAnika Therapeutics Comments on Patent Litigation BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Comments on Patent Litigation BEDFORD, Mass.--(BUSINESS WIRE)--April 26, 2011--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid ("HA") technology, announced today that Genzyme Corpor
Read more →ANIKAnika Therapeutics Reports 39% Total Revenue Growth in Fourth Quarter 2010 Orthobiologics Revenue Rises 40%, driven by record U.S. sales of ORTHOVISC BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 39% Total Revenue Growth in Fourth Quarter 2010 Revenue Rises 40%, driven by record U.S. sales of ORTHOVISC BEDFORD, Mass.--(BUSINESS WIRE)--March 9, 2011--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, and r
Read more →ANIKAnika Therapeutics Announces Date of Fourth-Quarter and Year-End 2010 Financial Results Conference Call and Provides Regulatory Timing Update Revises Anticipated Timeline for Pending U.S. Product Approvals and Clearances
Therapeutics Announces Date of Fourth-Quarter and Year-End 2010 Financial Results Conference Call and Provides Regulatory Timing Update Anticipated Timeline for Pending U.S. Product Approvals and Clearances and Final FDA Approval of Bedford Manufacturing Facility BEDFORD, Mas
Read more →ANIKAnika Therapeutics Appoints Industry Veteran Jeffery S. Thompson to Board of Directors Company Adds Seat to Board with Addition of Experienced Life Sciences CEO BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Appoints Industry Veteran Jeffery S. Thompson to Board of Adds Seat to Board with Addition of Experienced Life Sciences CEO BEDFORD, Mass.--(BUSINESS WIRE)--January 20, 2011--Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that it has appointed Jeffery S.
Read more →ANIKAnika Therapeutics Reports 29% Total Revenue Growth in Third Quarter 2010 FAB Integration and Manufacturing Consolidation Continue on Schedule; Company Files with FDA for 510(k) Approval of Three FAB Orthopedic Products
Therapeutics Reports 29% Total Revenue Growth in Third Quarter 2010 Integration and Manufacturing Consolidation Continue on Schedule; Company Files with FDA for 510(k) Approval of Three FAB Orthopedic BEDFORD, Mass.--(BUSINESS WIRE)--November 8, 2010--Anika Therapeutics, Inc.
Read more →ANIKAnika Therapeutics Reports 52% Total Revenue Growth in Second Quarter 2010 ORTHOVISC Sales Drive 24% Organic Growth Company Reports Progress on FAB Integration BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 52% Total Revenue Growth in Second Quarter 2010 Drive 24% Organic Growth Reports Progress on FAB Integration BEDFORD, Mass.--(BUSINESS WIRE)--August 9, 2010--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing, an
Read more →ANIKAnika Therapeutics Reports 35% Total Revenue Growth in First Quarter 2010 Strong Domestic Sales of ORTHOVISC Drive 18% Organic Product Growth; Company Completes Initial Steps in FAB Integration Plan BEDFORD, Mass.--(BUSI
Therapeutics Reports 35% Total Revenue Growth in First Quarter 2010 Domestic Sales of ORTHOVISC 18% Organic Product Growth; Company Completes Initial Steps in FAB BEDFORD, Mass.--(BUSINESS WIRE)--May 10, 2010--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for
Read more →ANIKAnika Therapeutics Reports 18% Revenue Growth in Fourth-Quarter 2009 Domestic Unit Sales of ORTHOVISC Grow to Record Quarterly Level Joint Health Revenue Increases 17% in Fourth Quarter BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 18% Revenue Growth in Fourth-Quarter 2009 Unit Sales of ORTHOVISC to Record Quarterly Level Health Revenue Increases 17% in Fourth Quarter BEDFORD, Mass.--(BUSINESS WIRE)--March 16, 2010--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for
Read more →ANIKAnika Therapeutics, Inc. Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Tel: 781-457-9000 Anika Therapeutics Acquires Fidia Advanced Biopolymers: A Leading Innovator in Hyaluronic Acid Based Tissue Engine
Sherwood, Ph.D., CEO Therapeutics Acquires Fidia Advanced Biopolymers: A Leading Innovator in Hyaluronic Acid Based Tissue Engineered Products Provides Novel Technology Platform for Growth & Broadens Portfolio and Development Pipeline to Develop Direct Sales Capability for M
Read more →ANIKAnika Therapeutics Reports 17% Revenue Growth in Third-Quarter 2009 Net Income Increases 37% BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports 17% Revenue Growth in Third-Quarter 2009 Income Increases 37% BEDFORD, Mass.--(BUSINESS WIRE)--October 27, 2009--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid ("HA") techno
Read more →ANIKAnika Therapeutics Reports Second-Quarter 2009 Results Domestic Unit Sales of ORTHOVISC Grow to Record Quarterly Level Joint Health Product Revenues Climb 17% Net Income Increases 18% BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports Second-Quarter 2009 Results Unit Sales of ORTHOVISC to Record Quarterly Level Health Product Revenues Climb 17% Income Increases 18% BEDFORD, Mass.--(BUSINESS WIRE)--July 22, 2009--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue
Read more →ANIKAnika Therapeutics Appoints Frank J. Luppino as Chief Operating Officer Seasoned Operations Executive Returns to Company BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Appoints Frank J. Luppino as Chief Operating Officer Operations Executive Returns to Company BEDFORD, Mass.--(BUSINESS WIRE)--May 26, 2009--Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced the appointment of Frank J. Luppino as chief operating officer. Lupp
Read more →ANIKAnika Therapeutics Reports First Quarter 2009 Results Revenues Rise 8% Led By Strong ORTHOVISC Sales Growth Joint Health Revenues Climb 25% BEDFORD, Mass.--(BUSINESS WIRE)
Therapeutics Reports First Quarter 2009 Results Rise 8% Led By Strong ORTHOVISC Health Revenues Climb 25% BEDFORD, Mass.--(BUSINESS WIRE)--April 29, 2009--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluro
Read more →ANIKAnika Therapeutics Reports Record Revenue for 2008 Total Revenue Grows 16% as Product Revenue Increases 23% for Full Year 2008 Accomplishments Include New Product Launches, Pipeline Achievements and Investments in New Ma
Therapeutics Reports Record Revenue for 2008 Revenue Grows 16% as Product Revenue Increases 23% for Full Year Accomplishments Include New Product Launches, Pipeline Achievements and Investments in New Manufacturing Facility to Accommodate Future Growth BEDFORD, Mass.--(BUSINE
Read more →ANIKAnika Therapeutics Reports 17% Increase in Third Quarter Product Revenue Company Reports Strong Initial Sales of ELEVESS in the U.S. Strong Domestic and European Sales Drive Increase in Joint Health Revenue BEDFORD, Mass
Therapeutics Reports 17% Increase in Third Quarter Product Revenue Reports Strong Initial Sales of ELEVESS in the U.S. Strong Domestic and European Sales Drive Increase in Joint Health Revenue BEDFORD, Mass.--(BUSINESS WIRE)--November 3, 2008--Anika Therapeutics, Inc. (Nasdaq
Read more →ANIKAnika Therapeutics Reports 28% Increase in Revenue for Second Quarter 2008 Joint Health Revenues Increase by 79% on Strong Domestic and European Sales BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: AN
Therapeutics Reports 28% Increase in Revenue for Second Quarter 2008 Health Revenues Increase by 79% on Strong Domestic and European Sales BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair
Read more →ANIKAnika Therapeutics Reports Strong Revenue Growth for First Quarter 2008 Revenues Rise 39%, with Gains Across All Product Lines Joint Health Revenues Increase by 56% on Strong Domestic and European Sales BEDFORD, Mass.--(
Therapeutics Reports Strong Revenue Growth for First Quarter 2008 Rise 39%, with Gains Across All Product Lines Health Revenues Increase by 56% on Strong Domestic and European Sales BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products
Read more →ANIKAnika Therapeutics, Inc. Renews Shareholder Rights Plan BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today that its Board of Directors has renewed its Shareholder Rights Plan. The re
Therapeutics, Inc. Renews Shareholder Rights Plan BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today that its Board of Directors has renewed its Shareholder Rights Plan. The renewed plan is similar to the original plan that had been in ex
Read more →ANIKAnika Therapeutics Reports Record Product Revenues for 2007 Strong Fourth Quarter Leads to Record Revenue for 2007 Company Strengthens its Worldwide Joint Health Franchise with Recent Start of U.S. Clinical Study of MONO
Therapeutics Reports Record Product Revenues for 2007 Fourth Quarter Leads to Record Revenue for 2007 Strengthens its Worldwide Joint Health Franchise with Recent Start of U.S. Clinical Study of MONOVISC and Launch of ORTHOVISC BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeu
Read more →ANIKAnika Therapeutics and Galderma Agree to Terminate License, Development and Supply Agreements Anika Therapeutics' to Reacquire Worldwide Rights to ELEVESS Brand BEDFORD, Mass.--(BUSINESS WIRE)
Anika Therapeutics and Galderma Agree to Terminate License, Development and Supply Agreements Anika Therapeutics' to Reacquire Worldwide Rights to ELEVESS Brand BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 20, 2007--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has
Read more →ANIKAnika Therapeutics Reports 33 Percent Increase in Third Quarter Product Revenues In Negotiation to Terminate Agreements with Galderma and Retain Worldwide Rights to ELEVESS Brand Receives European CE Mark for MONOVISC(R)
Anika Therapeutics Reports 33 Percent Increase in Third Quarter Product Revenues In Negotiation to Terminate Agreements with Galderma and Retain Worldwide Rights to ELEVESS Brand Receives European CE Mark for MONOVISC(R) Single-Injection Osteoarthritis Product WOBURN, Mass.-
Read more →ANIKAnika Therapeutics, Inc. Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO (781) 932-6616 ANIKA THERAPEUTICS PROMOTES RANDALL WILHOITE TO VICE PRESIDENT-OPERATIONS Replaces Departing Frank Luppino Woburn, M
Anika Therapeutics, Inc. Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO THERAPEUTICS PROMOTES RANDALL WILHOITE TO VICE PRESIDENT-OPERATIONS Replaces Departing Frank Luppino September 18, 2007 Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has promot
Read more →ANIKAnika Therapeutics Reports Second-Quarter Fiscal 2007 Financial Results ORTHOVISC Domestic Revenue Increases 66%; Product Revenue Increases 18% Sequentially WOBURN, Mass.--(BUSINESS WIRE)
Anika Therapeutics Reports Second-Quarter Fiscal 2007 Financial Results ORTHOVISC Domestic Revenue Increases 66%; Product Revenue Increases 18% Sequentially WOBURN, Mass.--(BUSINESS WIRE)--July 24, 2007--Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results
Read more →ANIKv072803_ex99-1.txt Anika Therapeutics Reports First-Quarter Fiscal 2007 Financial Results EPS and Net Income Increase 36% WOBURN, Mass., April 26 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today re
Anika Therapeutics Reports First-Quarter Fiscal 2007 Financial Results EPS and Net Income Increase 36% WOBURN, Mass., April 26 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results for the first quarter ended Anika reported product
Read more →ANIKCharles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Anika Therapeutics, Inc. (781) 932-6616 ANIKA THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR 2006 FINANCIAL RESULTS PRODUCT REVENUE INCREASES 17%
Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Anika Therapeutics, Inc. ANIKA THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR 2006 PRODUCT REVENUE INCREASES 17% FOR THE YEAR WOBURN, Mass., February 28, 2007 -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported
Read more →ANIKAnika Therapeutics Appoints Orthopedics Veteran John C. Moran to Board Of Directors WOBURN, Mass., Dec. 14 /PRNewswire-FirstCall/ Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has appointed John C. Mora
Anika Therapeutics Appoints Orthopedics Veteran John C. Moran to Board Of Directors Mass., Dec. 14 /PRNewswire-FirstCall/ Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has appointed John C. Moran as a new independent director on the Company s Board of Direct
Read more →ANIKAnika Therapeutics, Inc. Rodman & Renshaw 8 th Annual Healthcare Conference
Competitive Landscape Market Share Source: Anika, Frost & Sullivan 2004 Anika Ophthalmic Revenue 2002 - 2006 U.S. Viscoelastic - $162M * 2006 financial information is based on year-to-date results 9M 06 (in thousands) $9,907 $10,512 $11,533 $10,522 $8,433 0 2,000 4,000 6,000 8,00
Read more →ANIKCharles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Anika Therapeutics, Inc. (781) 932-6616 ANIKA THERAPEUTICS REPORTS THIRD QUARTER 2006
Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO Anika Therapeutics, Inc. ANIKA THERAPEUTICS REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS WOBURN, Mass., October 24, 2006 -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results for the third quarter and
Read more →ANIKAnika Therapeutics, Inc. UBS Global Life Sciences Conference
Competitive Landscape Market Share Source: Anika, Frost & Sullivan 2004 Anika Ophthalmic Revenue 2002 - 2006 U.S. Viscoelastic - $162M * 2006 financial information is based on year-to-date results YTD (in thousands) $9,907 $10,512 $11,533 $10,380 $5,482 0 2,000 4,000 6,000 8,000
Read more →ANIKAnika Therapeutics Reports Second Quarter 2006 Financial Results Reports Record Product Revenue for Second Consecutive Quarter WOBURN, Mass., July 24 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) toda
Anika Therapeutics Reports Second Quarter 2006 Financial Results Reports Record Product Revenue for Second Consecutive Quarter WOBURN, Mass., July 24 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results for the second quarter and si
Read more →ANIKAnika Therapeutics Announces Worldwide Development and Commercialization Agreement with Galderma Pharma WOBURN, Mass., July 5 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has
Anika Therapeutics Announces Worldwide Development and Commercialization Agreement with Galderma Pharma WOBURN, Mass., July 5 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has signed an exclusive worldwide development and commercializa
Read more →ANIKAnika Therapeutics Reports First Quarter 2006 Financial Results WOBURN, Mass., April 25 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results for the first quarter ended
Anika Therapeutics Reports First Quarter 2006 Financial Results WOBURN, Mass., April 25 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today reported financial results for the first quarter ended March 31, 2006. Product revenue was $6,266,000 for the first qu
Read more →ANIKAnika Therapeutics Reports Fourth Quarter and Full Year 2005 Financial Results
Anika Therapeutics Reports Fourth Quarter and Full Year 2005 Financial Results WOBURN, Mass. March 2, 2006--Anika Therapeutics, Inc. (NASDAQ:ANIK) today reported financial results for the fourth quarter and year ended December 31, 2005. Total revenue for the fourth quarter of
Read more →ANIKAnika Therapeutics, Inc. Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO (781) 932-6616 ANIKA THERAPEUTICS APPOINTS LIFE SCIENCES VETERAN RAYMOND J. LAND TO BOARD OF DIR
Charles H. Sherwood, Ph.D., CEO Kevin W. Quinlan, CFO ANIKA THERAPEUTICS APPOINTS LIFE SCIENCES VETERAN RAYMOND J. LAND TO BOARD OF DIRECTORS Woburn, Mass. January 25, 2006 Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has appointed Raymond J. Land as a new
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616 ANIKA THERAPEUTICS REPORTS THIRD QUAR
Anika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616 ANIKA THERAPEUTICS REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS WOBURN, Mass. October 18, 2005 Ani
Read more →ANIKAnika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena; Company Files Pre-Market Approval Application for Cosmetic Tissue Augmentation Product WOBURN, Mas
Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena; Company Files Pre-Market Approval Application for Cosmetic Tissue Augmentation Product WOBURN, Mass. (BUSINESS WIRE) Sept. 1, 2005 Anika Therapeutics, Inc
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616 ANIKA THERAPEUTICS REPOR
Contacts: Anika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616 THERAPEUTICS REPORTS SECOND 2005 FINANCIAL RESULTS WOBURN, Mass. July 27, 2005 Anika T
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616
NEWS RELEASE Contacts: Anika Therapeutics, Inc. PondelWilkinson Inc. Charles H. Sherwood, Ph.D., CEO Rob Whetstone (310) 279-5963 Kevin W. Quinlan, CFO Wade Huckabee (310) 279-5971 (781) 932-6616 THERAPEUTICS ANNOUNCES ADDITION OF WOBURN, Mass. July 12, 2005 Anika Ther
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Charles H. Sherwood, Ph.D. Susan Klein (508) 358-4315 Chief Executive Officer Rob Whetstone (310) 279-5963 (781) 932-6616 x205 ANIKA THERAPEUTICS REPORTS 19
Contacts: Anika Therapeutics, Inc. PondelWilkinson Charles H. Sherwood, Ph.D. Susan Klein (508) 358-4315 Chief Executive Officer Rob Whetstone (310) 279-5963 (781) 932-6616 x205 ANIKA THERAPEUTICS REPORTS 19% INCREASE FIRST QUARTER REVENUE WOBURN, Mass. April 27, 2005 A
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS REPORTS CONTINUED REVENUE AND N
Contacts: Anika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS REPORTS CONTINUED REVENUE AND NET GROWTH FOR 2004 FOURTH QUARTER AND FULL YEAR Mass. - February
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS SIGNS MULTI-YEAR SUPPLIER AGREE
Contacts: Anika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS SIGNS MULTI-YEAR SUPPLIER AGREEMENT OrthoVisc US marketing agreement milestone payment received Mass
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS ANNOUNCES ADDITION OF CAROL TOT
Contacts: Anika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS ANNOUNCES ADDITION OF CAROL TOTH, AS VICE PRESIDENT OF RESEARCH AND DEVELOPMENT WOBURN, Mass. No
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS REPORTS 74% REVENUE INCREASE TO
Contacts: Anika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS REPORTS 74% REVENUE INCREASE TO $6.4 MILLION FOR 2004 THIRD QUARTER Mass. October 29, 2004 Anika The
Read more →ANIKAnika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 ANIKA THERAPEUTICS ANNOUNCES ADDITION OF NEW BUSIN
NEWS RELEASE Contacts: Anika Therapeutics, Inc. PondelWilkinson Klein Charles Sherwood, Ph.D., CEO Susan Klein (508) 358-4315 (781) 932-6616 Rob Whetstone (310) 279-5963 THERAPEUTICS ANNOUNCES ADDITION OF NEW BUSINESS DEVELOPMENT EXECUTIVE; DEPARTURE OF CHIEF FINANCIAL O
Read more →Competitive Position
How ANIK ranks across every disease it competes inCompetitive Position is a premium feature
See how ANIK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial